Emergent BioSolutions | EBS - Nettoeinkommen

Aktienkurs
8.81
Täglich Wechseln
0.19 2.20%
Monatlich
10.13%
Jährlich
94.05%
Q2 Prognose
8.43




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 49.34M 33.42M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amarin USD -1.22M 6.51M 2025-12
ANI Pharmaceuticals USD 32.35M 6.08M 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Coherus Biosciences USD -37.64M 2.11M 2025-12
Emergent BioSolutions USD -261.3M 78.3M 2023-06
Exelixis USD 193.58M 8.73M 2025-09
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
Lonza CHF 426M 119M 2025-06
Merck USD 2.96B 2.82B 2025-12
Moderna USD -200M 625M 2025-09
Myriad Genetics USD -7.9M 19.5M 2025-12
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Pacira USD 1.64M 3.8M 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Sanofi EUR -801M 3.6B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Xoma USD -17.24M 33.23M 2024-09